← 返回前沿论文

缺氧预处理间充质干细胞来源小细胞外囊泡通过调控 SIRT1/Nrf2/HO-1 通路抑制脊髓损伤后神经元死亡

英文原题:Hypoxic-preconditioned mesenchymal stem cell-derived small extracellular vesicles inhibit neuronal death after spinal cord injury by regulating the SIRT1/Nrf2/HO-1 pathway.

PubMed 2024/08/23(内容时间) Front Pharmacol Q1 · IF 5.4(JCR 2025)

研究概要

我们的研究为H-sEVs对SCI后神经元氧化应激和凋亡的影响提供了有价值的见解。这些发现强调了基于H-sEVs的疗法对SCI的潜在临床意义。

研究思路结论见上方概要

氧化应激和神经元凋亡显著促进脊髓损伤(SCI)的病理生理级联反应。然而,缺氧预处理的间充质干细胞来源的小细胞外囊泡(H-sEVs)在促进SCI修复中的作用仍不清楚。因此,本研究旨在探讨H-sEVs对SCI后神经元氧化应激和凋亡反应的调控作用。

采用Basso-Beattie-Bresnahan(BBB)评分、神经电生理监测和Catwalk步态分析等行为学评估方法,评估SCI大鼠给予H-sEVs后的效果。检测氧化应激指标(包括超氧化物歧化酶[SOD]、总抗氧化能力[T-AOC]和丙二醛[MDA])。通过Nissl染色评估神经元存活情况,同时采用免疫组化染色检测sirtuin 1(SIRT1)的表达水平。此外,使用苏木精-伊红(HE)染色进行病灶大小的组织学评估。分别通过免疫荧光染色和western blot进行Tunel细胞凋亡染色及凋亡相关蛋白(B细胞淋巴瘤-2 [Bcl2]和BCL2相关X [Bax])的分析。进一步地,使用PC12细胞建立氧化应激模型,并通过流式细胞术和western blot分析评估凋亡水平。重要的是,为确定SIRT1的关键作用,我们通过慢病毒转染在PC12细胞中进行SIRT1敲除实验,随后进行western blot检测。

利用这些行为学评估,我们观察到H-sEVs治疗后有显著的功能改善。Nissl染色显示,H-sEVs治疗促进了神经元存活。此外,我们发现H-sEVs有效降低了SCI后的氧化应激水平。HE染色表明,H-sEVs能够减小损伤面积。免疫组化分析显示,H-sEVs增强了SIRT1表达。此外,Tunel细胞凋亡染色和凋亡相关蛋白的western blot分析证实了H-sEVs的抗凋亡作用。使用PC12细胞进一步证实了H-sEVs的神经保护特性,即显著抑制神经元死亡并减轻氧化应激。值得注意的是,PC12细胞中SIRT1敲除逆转了H-sEVs治疗诱导的抗氧化应激效应。此外,我们阐明了下游Nrf2/HO-1信号通路的参与。

展开英文摘要原文

BACKGROUND: Oxidative stress and apoptosis of neurons significantly contribute to the pathophysiological cascade of spinal cord injury (SCI). However, the role of hypoxic-preconditioned mesenchymal stem cell-derived small extracellular vesicles (H-sEVs) in promoting SCI repair remains unclear. Hence, the present study aims to investigate the regulatory effects of H-sEVs on neuronal oxidative stress and apoptotic responses following SCI. METHODS: The administration of H-sEVs of SCI rats was assessed using behavioral evaluations such as Basso-Beattie-Bresnahan (BBB) scores, neuroelectrophysiological monitoring, and Catwalk gait analysis. Indices of oxidative stress (including superoxide dismutase [SOD], total antioxidant capacity [T-AOC], and malondialdehyde [MDA]) were measured. Neuronal survival was evaluated through Nissl staining, while the expression level of sirtuin 1 (SIRT1) was examined using immunohistochemical staining. Additionally, histological evaluation of lesion size was performed using hematoxylin-eosin (HE) staining. Tunel cell apoptosis staining and analysis of apoptosis-associated proteins (B-cell lymphoma-2 [Bcl2] and BCL2-Associated X [Bax]) were conducted through immunofluorescence staining and western blot, respectively. Furthermore, the model of oxidative stress was established using PC12 cells, and apoptosis levels were assessed via flow cytometry and western blot analysis. Importantly, to ascertain the critical role of SIRT1, we performed SIRT1 knockout experiments in PC12 cells using lentivirus transfection, followed by western blot. RESULTS: Using those behavioral evaluations, we observed significant functional improvement after H-sEVs treatment. Nissl staining revealed that H-sEVs treatment promoted neuronal survival. Moreover, we found that H-sEVs effectively reduced oxidative stress levels after SCI. HE staining demonstrated that H-sEVs could reduce lesion area. Immunohistochemical analysis revealed that H-sEVs enhanced SIRT1 expression. Furthermore, Tunel cell apoptosis staining and western blot analysis of apoptosis-related proteins confirmed the anti-apoptotic effects of H-sEVs. The PC12 cells were used to further substantiate the neuroprotective properties of H-sEVs by significantly inhibiting neuronal death and attenuating oxidative stress. Remarkably, SIRT1 knockout in PC12 cells reversed the antioxidant stress effects induced by H-sEVs treatment. Additionally, we elucidated the involvement of the downstream Nrf2/HO-1 signaling pathway. CONCLUSION: Our study provides valuable insights into the effects of H-sEVs on neuronal oxidative stress and apoptosis after SCI. These findings underscore the potential clinical significance of H-sEVs-based therapies for SCI.

论文信息

作者
Rao J、Xie H、Liang Z、Yang Z、Chen P、Zhou M、Xu X、Lin Y
单位
Department of Neurosurgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.China
期刊
Frontiers in pharmacology2024
原文标识
PubMed 39246654 · DOI 10.3389/fphar.2024.1419390